[Prognostic factors for patients with brain metastases]

Approximately 20 to 40 % of patients with metastatic cancer will develop brain metastases (BM) during the disease course. Whole-brain radiation therapy (WBRT) is considered the standard treatment for most patients, particularly those with extensive intracranial disease, providing symptom relief and increasing median and overall survival. Despite WBRT, the prognosis for the general population of patients with BM remains poor, with a median survival time of approximately five months. Several studies have examined the relative contribution of patient characteristics to survival and have attempted to identify subgroups of patients with substantially different outcomes in order to tailor therapy and to influence the design, stratification and interpretation of future clinical trials. Here, we review the main prognostic factors and prognostic scores in patients with BM and the value and limits of these prognostic scores in clinical practice.